Updates from Addex Therapeutics for 2024 Financial Results
Today, Addex Therapeutics (SIX/NASDAQ: ADXN) has unveiled that they will release their Full-Year 2024 Financial Results soon. This announcement comes as part of their commitment to transparency and communication with stakeholders. The results are set to be made public on a specific date in the near future, promising insights into their financial health and future prospects.
Tim Dyer, the CEO, alongside Mikhail Kalinichev, the Head of Translational Science, will lead a conference call that is designed to engage investors, analysts, and the media. These discussions will not only cover the financial outcomes but also provide a valuable business update, highlighting their impressive product pipeline.
Key Details of the Upcoming Conference Call
The conference call is scheduled to take place at 16:00 CEST. Participants will need to register in advance to gain access to this important session. During this time, valuable insights into the company’s ongoing projects and future directions will be shared.
Here are a few steps to follow for joining the call:
Registration Instructions
1. Participants must register ahead of time using the link provided during the announcement. Once registered, each individual will receive unique dial-in numbers and a Personal Identification Number (PIN).
2. It’s recommended to join the call about ten minutes early using the details sent via email during the registration process. Alternatively, the 'call me' feature can be utilized for added convenience.
How to Access the Webcast
There's a specific URL for attendees to register for the webcast, ensuring a seamless experience during the call. This approach reflects Addex's commitment to keeping all parties informed and engaged with their progress.
Insights on Addex Therapeutics
Addex Therapeutics specializes in the development of innovative small molecule allosteric modulators aimed at addressing significant neurological disorders. Their flagship candidate, dipraglurant, is currently being evaluated for its efficacy in recovery from brain injuries, including those following strokes.
Additionally, the company is in a strategic partnership with Indivior, which is focusing on developing a GABAB PAM drug candidate for substance use disorders. Another exciting avenue for Addex includes their independent GABAB PAM program targeting chronic cough, which shows promise in medical solutions.
Investment and Collaborative Ventures
Addex also holds a 20% stake in Neurosterix LLC, a company dedicated to advancing a range of allosteric modulator programs, including treatments focused on schizophrenia and neurocognitive disorders. This diverse portfolio underscores their dynamic approach to tackling a multitude of neurological challenges.
Contact Information for Addex
For those interested in more information or have queries regarding Addex Therapeutics, here is the contact information:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 7968 022075
Email: msinclair@halsin.com
Frequently Asked Questions
What are Addex Therapeutics' main areas of focus?
Addex Therapeutics specializes in developing allosteric modulators for neurological disorders, including programs for brain injury recovery and substance use disorders.
When will the Full-Year 2024 Financial Results be announced?
The financial results are set to be made public soon, and details are shared via a conference call on the release date.
How can I participate in the conference call?
To join, you will need to register in advance using the link provided by Addex to receive dial-in information and a Personal PIN.
What is dipraglurant?
Dipraglurant is Addex's lead drug candidate, which is currently being studied for its role in brain injury recovery.
Where can I find more information about Addex Therapeutics?
You can gather more details about Addex’s programs and developments on their official website at www.addextherapeutics.com.
